Prof Marc Brown has over 30 years experience in topical (skin, nail, eye, lung, nose and other mucousal membranes) and transdermal formulation development in the pharmaceutical development sector. After working in North America for a few years , in 1999 he co-founded MedPharm and, as CSO, was the guiding force behind all of MedPharm’s scientific developments and intellectual property until its sale in 2022. He has been Professor of Pharmaceutics and Toxicology in the School of Pharmacy, University of Hertfordshire since 2006 , has visiting/honorary professorships at the Universities of Reading and King’s College London and was awarded Professor Emeritus status in 2022 . His research interests lie mainly in drug delivery to the skin, nail and airways and has one text book, over 200 publications and 30 patents describing his work. To date, he has been involved in the pharmaceutical development of over 55 medicinal products that are now on the market in Europe, America and Japan. He currently acts as CSO of Mosanna Therapeutics AG, is a scientific advisor for numerous pharma companies and has been an expert witness in various patent litigation cases in the US and Europe.

Dr Sandrien Janssens is a pharmacist, with a Ph.D. in enabling formulation technologies, and a certified Qualified Person with over 20 years of CMC (small drug and biologics) experience in analytics, product development, drug substance & drug product transfer and scale up, performance testing, regulatory and quality support of both IMP and commercial supplies of oral, ophthalmic, sterile, topical and respiratory (nasal and pulmonary) medicines. To date, whilst working at J and J, MSD, Galapagos, Oxurion and Mosanna Therapeutics, Sandrien has been directly involved in the development and manufacture of 30 drug products that have entered clinical evaluation/commercialisation.

Margarida Miranda graduated in Pharmaceutical Sciences (University of Lisbon) and completed her PhD in Pharmaceutical Technology (University of Coimbra, Portugal) and has published 18 papers, 4 book chapters and edited 1 book on the field of topical drug delivery. After completing her Ph.D she translated her research into the R&D department of Laboratórios Basi, where she has implemented IVRT/IVPT methods within a Quality Management System. In addition, she actively contributed to the definition of strategies to demonstrate topical bioequivalence, in accordance with the current European and American guidelines and has been involved in the development, submission and approval of several topical generic products in the European market. Whilst consulting for MLBT she is also Assistant Professor of Pharmaceutical Technology, as well as Cosmetic Science, at Egas Moniz School of Health & Science.

Dr. Kuljit Bhatia is a US based product development expert with over 25 years in the pharmaceutical, biotech and consumer health industry. He holds a Ph.D. in Pharmaceutical sciences with a focus on drug delivery. Dr. Bhatia's experience includes development of new-drug, generic-drug,  and OTC pharmaceuticals for all dosage forms  and has been directly involved in developing and commercializing  ca. 100 NDAs//ANDAs.  As such Dr. Bhatia has a broad level of experience in formulation, analytics, product development, drug substance and drug product transfer, scale-up processes, performance testing, regulatory strategy/compliance, clinical strategy and quality assurance gained with Viatris (Mylan), DPT Laboratories, Nycomed, Fougera/Sandoz, and Medicis Inc. His expertise also extends across business development, project management, IP landscape assessment and merger & acquisitions. He was a critical member of the team in the sale of Fougera to Sandoz (2011) and DPT to Renaissance-Round Table Partners (2012) and then Mylan Inc (2016).